List view / Grid view
When France's ATU reform was implemented, some viewed it as restrictive. Here, Cécile Matthews and Charlotte Capdevila explore the reform’s impact on early access to oncology drugs and products for rare diseases.
The top 20 biopharma companies averaged a market capitalisation decline of $3.45 trillion in Q2 to $3.14 trillion in Q3 2022, says GlobalData.
The EMA's human medicines committee has released its results for the December meeting, suggesting which therapies should receive marketing authorisation.
This August saw nine new green lights from the FDA, all small molecules, which makes up a third of the approvals this year.
